Cross-linked polysaccharide gels

• US 20100035838A1
• Filed: 09/18/2007
• Published: 02/11/2010
• Est. Priority Date: 09/19/2006
• Status: Abandoned Application

• Current Assignee: Geoffrey Kenneth Heber, Nicholas Patrick John Stamford
• Original Assignee: Geoffrey Kenneth Heber, Nicholas Patrick John Stamford
• Inventors: Heber, Geoffrey Kenneth, Stamford, Nicholas Patrick John
• Application Number:
  US12/442,073
• Publication Number:
  US 20100035838A1
• Time in Patent Office: Days
• US Class Current: 514/54
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08B 15/005 Crosslinking of cellulose derivatives
• CPC Class Codes: C08B 31/003 Crosslinking of starch
• CPC Class Codes: C08B 31/006 Crosslinking of derivatives of starch
• CPC Class Codes: C08B 37/0042 Carragenan or carragen, i.e. D-galactose and 3,6-anhydro-D-galactose, both partially sulfated, e.g. from red algae Chondrus crispus or Gigantia stellata; kappa-Carragenan; iota-Carragenan; lambda-Carragenan; Derivatives thereof
• CPC Class Codes: C08B 37/0045 alpha-D-Galacturonans, e.g. methyl ester of (alpha-1,4)-linked D-galacturonic acid units, i.e. pectin, or hydrolysis product of methyl ester of alpha-1,4-linked D-galacturonic acid units, i.e. pectinic acid; Derivatives thereof
• CPC Class Codes: C08B 37/0069 Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
• CPC Class Codes: C08B 37/0072 Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
• CPC Class Codes: C08B 37/0075 Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
• CPC Class Codes: C08B 37/0087 Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
• CPC Class Codes: C08J 3/075 Macromolecular gels

Abstract

The present invention relates to a process for preparing a cross-linked polysaccharide gel comprising contacting a polysaccharide with a cross-linking agent and a masking agent to form a cross-linked polysaccharide gel having resistance to degradation under physiological conditions.

Claims

1-28. -28. (canceled)

29. A process for preparing a cross-linked polysaccharide gel having resistance to enzymatic degradation under physiological conditions, the process comprising:

contacting a polysaccharide with a cross-linking agent under conditions to form a cross-linked polysaccharide gel, and

contacting the polysaccharide with a masking agent selected from the group consisting of a monofunctional epoxide and an alkyl vinyl sulfone;

so as to form a cross-linked polysaccharide gel having resistance to enzymatic degradation.

30. The process according to claim 29, wherein the contacting with a cross-linking agent and the contacting with a masking agent occur substantially at the same time.

31. The process according to claim 29, wherein the contacting with a masking agent occurs after the contacting with a cross-linking agent.

32. The process according to claim 29, wherein the polysaccharide is contacted with the cross-linking agent under alkaline conditions to form a cross-linked polysaccharide substantially cross-linked by ether bonds.

33. The process according to claim 29, further comprising:

drying the cross-linked polysaccharide without substantially removing the cross-linking agent or the masking agent to form a cross-linked polysaccharide matrix; and

neutralising the cross-linked polysaccharide matrix with an acidic medium to form the cross-linked polysaccharide gel.

34. The process according to claim 29, wherein the polysaccharide is selected from the group consisting of hyaluronic acid, chondroitin sulphate, heparin, maltodextrins, cellodextrins, cellulose, chitosan, glucomannan, pectin, xanthan, algiinic acid, carboxymethyl cellulose, carboxymethyl dextran, and carrageenans.

35. The process according to claim 34, wherein the polysaccharide is hyaluronic acid.

36. The process according to claim 29, wherein the cross-linking agent is selected from the group consisting of aldehydes, epoxides, glycidyl ethers, polyaziridyl compounds, and divinylsulfones.

37. The process according to claim 36, wherein the cross-linking agent is selected from the group consisting of ethylene glycol diglycidyl ether, 1,4-butanediol diglycidyl ether, 1.4-bis(2,3-epoxypropoxy)butane, 1,4-bisglycidyloxybutane, 1,2-bis(2,3-epoxypropoxy)ethylene or 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane.

38. The process according to claim 37, wherein the cross-linking agent is 1,4-butanediol diglycidyl ether.

39. The process according to claim 29, wherein the masking agent is selected from the group consisting of ethylene oxide, propylene oxide, ethyl vinyl sulfone, methyl vinyl sulfone, and glycidol.

40. The process according to claim 39, wherein the masking agent is glycidol or ethyl vinyl sulfone.

41. The process according to claim 40, wherein the masking agent is glycidol.

42. The process according to claim 39, wherein the cross-linking agent and masking agent are used under alkaline conditions.

43. The process according to claim 32, wherein the alkaline conditions have a pH in the range of about 8 to 14.

44. The process according to claim 42, wherein the alkaline conditions have a pH in the range of about 8 to 14.

45. The process according to claim 32, wherein the alkaline conditions are formed by from 0.1 to 1 w/v percent of NaOH or KOH.

46. The process according to claim 29, wherein the step of contacting the polysaccharide with the cross-linking agent comprises between 1 and 10 w/v percent polysaccharide and between 0.05 and 1.0 w/v percent cross-linking agent.

47. The process according to claim 46, comprising about 4 w/v percent polysaccharide.

48. The process according to claim 47, comprising about 0.1 w/v percent cross-linking agent.

49. The process according to claim 29, wherein each contacting step is carried out at a temperature in the range 0-100°

C.

50. The process according to claim 49, wherein each contacting step is carried out at a temperature of at least about 40°

C.

51. The process according to claim 29, wherein the cross-linked polysaccharide is dried.

52. The process according to claim 33, wherein the acidic medium comprises acetic acid or hydrochloric acid.

53. The process according to claim 29, further comprising:

washing the cross-linked polysaccharide gel with a water-miscible solvent.

54. The process according to claim 53, wherein the water-miscible solvent is isopropyl alcohol.

55. The process according to claim 33, wherein following the neutralisation step the cross-linked polysaccharide gel is dried and optionally reconstituted.

56. The process according to claim 55, wherein the dried cross-linked polysaccharide gel is reconstituted in phosphate buffered saline.

57. A method of augmenting tissue comprising administering to a subject a cross-linked polysaccharide gel prepared by the process of claim 29.

58. A method of treating a subject in need thereof, comprising administering to the subject an effective amount of a cross-linked polysaccharide gel prepared by the process of claim 29.